Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo- L- Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag121 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Brittany A Riggle und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Antimalarials, Diazooxonorleucine, Malaria, Cerebral. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, US National Institutes of Health, Intramural Research Program.
Abstract (Originalsprache)
Background
Cerebral malaria (CM) is a common cause of febrile coma among African children. Despite treatment with highly efficacious intravenous artesunate, CM remains associated with high mortality and neurologic sequelae. In a mouse CM model, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) demonstrated robust efficacy as a potential adjuvant therapy. Before testing DON in children with CM, we investigated tolerability in African adults, including individuals with malaria.
Methods
We conducted an open-label, prospective, dose-escalation, phase 1 clinical trial of single-dose intravenous DON in Blantyre, Malawi. Participants included healthy adults and adults with uncomplicated malaria, enrolled in dose-cohorts of 10 and administered DON at 0.1, 1.0, 5.0, or 10 mg/kg. We assessed adverse events (AEs) and plasma pharmacokinetics.
Results
Forty healthy adults and 38 adults with uncomplicated malaria received DON. Transient, asymptomatic creatinine elevation occurred 12 hours postinfusion in 18% of all participants. Nausea and vomiting were uncommon at 0.1 and 1.0 mg/kg but occurred more frequently at 5.0 and 10 mg/kg DON. All DON-related AEs resolved rapidly, without sequelae, and did not significantly differ between healthy and uncomplicated malaria participants. In healthy adults, maximum plasma concentrations increased proportional to dose, but adults with malaria had greater than dose-proportional increases. Terminal half-life ranged from 1.7 to 4.1 hours.
Conclusions
DON was well tolerated in healthy adults and adults with uncomplicated malaria. Higher doses were associated with transient gastrointestinal AEs. Pharmacokinetics were minimally influenced by malaria disease. These results provide critical data to guide dosing strategies for adjunctive DON in children with CM. Clinical Trials Registration. NCT05478720.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
- Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
- Department of Internal Medicine, Kamuzu University of Health Sciences, Blantyre, Malawi.
- Johns Hopkins Drug Discovery, Johs Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Brittany A Riggle, Athanasios Chamzas, Mathangi Gopalakrishnan, Osward M Nyirenda, Nginache Nampota-Nkomba, Rana Rais, Barbara Slusher, Neshen Moodley, Nicole F O'Brien, Matthew B Laurens, Douglas G Postels
Förderung
- NIAID NIH HHS
- US National Institutes of Health
- Intramural Research Program
- NHLBI NIH HHS
- National Institute of Allergy and Infectious Diseases
- Division of Intramural Research
Zitieren
APA
Riggle, B. A., Chamzas, A., Gopalakrishnan, M., Nyirenda, O. M., Nampota-Nkomba, N., Mallewa, J. E., Masonga, R., Manyozo, C., Zuze, K., Liomba, A. M., Alt, J., Rais, R., Slusher, B., Moodley, N., Miller, L. H., Pierce, S. K., O'Brien, N. F., Laurens, M. B., & Postels, D. G. (2026). Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo- L- Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag121
Vancouver
Riggle BA, Chamzas A, Gopalakrishnan M, Nyirenda OM, Nampota-Nkomba N, Mallewa JE, et al. Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo- L- Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag121
BibTeX
@article{Riggle2026,
author = {Riggle, Brittany A and Chamzas, Athanasios and Gopalakrishnan, Mathangi and Nyirenda, Osward M and Nampota-Nkomba, Nginache and Mallewa, Jane E and Masonga, Rhoda and Manyozo, Cynthia and Zuze, Kingsley and Liomba, Alice M and Alt, Jesse and Rais, Rana and Slusher, Barbara and Moodley, Neshen and Miller, Louis H and Pierce, Susan K and O'Brien, Nicole F and Laurens, Matthew B and Postels, Douglas G},
title = {Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo- L- Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag121}
}
EUVIMED